Abstract Library

#3081 An Atypical Presentation of a Neuroendocrine Carcinoma of Unknown Origin

Introduction: Neuroendocrine carcinomas (NEC) of unknown primary site are uncommon. Most arise from an occult/clinically undetectable primary. Primary NEC of genitourinary tract are rare. High-grade (HG) carcinoms, are rapidly growing and aggressive but usually responsive to platinum-based combination chemotherapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Da Silva Dias D, Gosálbez B,

Keywords: .,

#3077 Insights into the Practice Patterns, Challenges and the Role of a Shared Care Model in the Management of Neuroendocrine (NET) Patients in the Community

Introduction: Management of NET patients often involves a multidisciplinary approach,requiring collaboration between referring oncologists,surgeons,endocrinologists locally and NET specialty centers (NSC).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Yelamanchili R

Authors: Radhika Y, Chan D, Thawer A, Lo D, Singh S,

Keywords: Shared care, NET, Local Medical Oncologists, NET specialty centers,

#3073 The Role of Rb as a Prognostic Factor in Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (G3NEC) Treated by First Line Platinum-Etoposide Combination, a Retrospective Study

Introduction: G3NEC are heterogeneous and aggressive diseases which can arise in different organs. Platinum-etoposide combination is used as first line treatment whatever the primary. Rb has been suggested to be a predictive/prognostic factor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hadoux J

Authors: Hadoux J, Kanaan C, Planchard D, Malka D, Ducreux M,

Keywords: Neuroendocrine carcinoma, Platinum-etoposide, Rb,

#3072 Rb and p53 Status Determination by Immunochemistry Is Complementary in Routine Practice to Genetic Testing of Neuroendocrine Neoplasms

Introduction: Rb and p53 status may help distinguishing well from poorly differentiated neuroendocrine neoplasms (NEN) and may predict response to chemotherapy. Studies correlating Rb/p53 genetic and immunohistochemistry were performed on high-quality frozen samples with high throughput techniques efficient for copy number determination. This situation differs from routine practice in which small deletions may be hard to detect on formalin-fixed paraffin-embedded (FFPE) samples with a gene panel approach.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cros J

Authors: Chen R, Lacroix L, De Rycke O, Lacombe C, Cazes A,

Keywords: rb, p53, aggressive neuroendocrine tumors, biomarker,

#3068 WHO Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasm (GEP-NEN): Data from 358 Patients of the Spanish Group of Neuroendocrine and Endocrine Tumors Registry (R-GETNE)

Introduction: RGETNE national NEN Registry comprises 74 hospitals from all regions of Spain.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Garcia Carbonero R, Jimenez-Fonseca P, Benavent M, Alonso V, Crespo G,

Keywords: G3 NEN, epidemiology, survival, patterns of care, response to chemotherapy,